© 1993 by Oxford University Press
Journal of the National Cancer Institute, Vol. 85, No. 8, 622-632,
April 21, 1993
© 1993 Oxford University Press
Prospective Randomized Trial of High-Dose Interleukin-2 Alone or in Conjunction With Lymphokine-Activated Killer Cells for the Treatment of Patients With Advanced Cancer
Surgery Branch, Division of Cancer Treatment, National Cancer Institute Bethesda, Md
Biostatistics and Data Management Section, Clinical Oncology Program, Division of Cancer Treatment, National Cancer Institute Bethesda, Md
Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health Bethesda
Correspondence to: Steven A. Rosenberg, M.D., Ph.D., Bldg. 10 Rm. 2B42, National Institutes of Health, Bethesda, MD 20892.
Background: Treatment using interleukin-2 (IL-2) alone or in conjunction with lymphokine-activated killer (LAK) cells has been shown to mediate disease regression in selected patients with advanced cancer. Purpose: This prospective randomized trial was designed to determine whether the administration of LAK cells in conjunction with high-dose IL-2 alters response and survival rates, compared with those for IL-2 alone, in patients with advanced cancer. Methods: The 181 patients who had metastatic cancer that had failed to respond to standard therapy or who had disease for which no effective therapy existed received treatment with high-dose IL-2 alone or with LAK cells plus IL-2. Both treatment groups were to receive the same dose of IL-2 administered according to the same schedule. IL-2 doses were omitted depending on the tolerance of the patient. Of the 181 patients, 97 had renal cell cancer and 54 had melanoma. Results: Median potential follow-up was 63.2 months. There were 10 complete responses among the 85 assessable patients who received IL-2 plus LAK cells, compared with four among the 79 who received IL-2 alone. There were 14 and 12 partial responses, respectively. Complete response continues in seven patients at 50–66 months. The 36-month actuarial survival with IL-2 plus LAK cells was 31%, compared with 17% with IL-2 alone (two-sided P value [P2] = .089). A trend toward improved survival was seen for patients with melanoma who received IL-2 plus LAK cells, compared with those who received IL-2 alone (24-month survival: 32% versus 15%; 48-month survival: 18% versus 4%; P2 = .64). None of 26 patients with melanoma who received IL-2 alone are alive; five of 28 who received IL-2 plus LAK cells are alive, and three continue in complete response. No difference in survival was seen in patients with renal cell cancer in the two treatment groups. There were six treatment-related deaths (3.3%); three were due to myocardial infarction. Other toxic effects resolved by discontinuation of IL-2. Many toxic effects were related to increased vascular permeability induced by IL-2. Conclusions: Some patients with metastatic cancer have prolonged remission when they are treated with highdose IL-2 alone or in conjunction with LAK cells. Our results suggest a trend toward increased survival when IL-2 is given with LAK cells in patients with melanoma, but no trend was observed for patients with renal cell cancer. Implications: As these studies continue, efforts are underway to develop improved immunotherapies using tumor-infiltrating lymphocytes (TIL) and genemodified TIL. [J Natl Cancer Inst 85: 622–632, 1993]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. J. Pegram, J. T. Jackson, M. J. Smyth, M. H. Kershaw, and P. K. Darcy Adoptive Transfer of Gene-Modified Primary NK Cells Can Specifically Inhibit Tumor Progression In Vivo J. Immunol., September 1, 2008; 181(5): 3449 - 3455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Sosman, C. Carrillo, W. J. Urba, L. Flaherty, M. B. Atkins, J. I. Clark, J. Dutcher, K. A. Margolin, J. Mier, J. Gollob, et al. Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2-Positive Advanced Melanoma J. Clin. Oncol., May 10, 2008; 26(14): 2292 - 2298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Schlom, J. L. Gulley, and P. M. Arlen Paradigm Shifts in Cancer Vaccine Therapy Experimental Biology and Medicine, May 1, 2008; 233(5): 522 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Costa and H. A. Drabkin Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies Oncologist, December 1, 2007; 12(12): 1404 - 1415. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Schlom, P. M. Arlen, and J. L. Gulley Cancer Vaccines: Moving Beyond Current Paradigms Clin. Cancer Res., July 1, 2007; 13(13): 3776 - 3782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zamai, C. Ponti, P. Mirandola, G. Gobbi, S. Papa, L. Galeotti, L. Cocco, and M. Vitale NK Cells and Cancer J. Immunol., April 1, 2007; 178(7): 4011 - 4016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Yang and R. Childs Immunotherapy for Renal Cell Cancer J. Clin. Oncol., December 10, 2006; 24(35): 5576 - 5583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Parton, M. Gore, and T. Eisen Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer J. Clin. Oncol., December 10, 2006; 24(35): 5584 - 5592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Khan, J. K. Stauffer, R. Williams, J. A. Hixon, R. Salcedo, E. Lincoln, T. C. Back, D. Powell, S. Lockett, A. C. Arnold, et al. Proteasome Inhibition to Maximize the Apoptotic Potential of Cytokine Therapy for Murine Neuroblastoma Tumors J. Immunol., May 15, 2006; 176(10): 6302 - 6312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. S. van Houdt, J. J. Oudejans, A. J.M. van den Eertwegh, A. Baars, W. Vos, B. A. Bladergroen, D. Rimoldi, J. J.F. Muris, E. Hooijberg, C. M. Gundy, et al. Expression of the Apoptosis Inhibitor Protease Inhibitor 9 Predicts Clinical Outcome in Vaccinated Patients with Stage III and IV Melanoma Clin. Cancer Res., September 1, 2005; 11(17): 6400 - 6407. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Divgi, J. A. O'Donoghue, S. Welt, J. O'Neel, R. Finn, R. J. Motzer, A. Jungbluth, E. Hoffman, G. Ritter, S. M. Larson, et al. Phase I Clinical Trial with Fractionated Radioimmunotherapy Using 131I-Labeled Chimeric G250 in Metastatic Renal Cancer J. Nucl. Med., August 1, 2004; 45(8): 1412 - 1421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Blattman and P. D. Greenberg Cancer Immunotherapy: A Treatment for the Masses Science, July 9, 2004; 305(5681): 200 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Igarashi, J. Wynberg, R. Srinivasan, B. Becknell, J. P. McCoy Jr, Y. Takahashi, D. A. Suffredini, W. M. Linehan, M. A. Caligiuri, and R. W. Childs Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells Blood, July 1, 2004; 104(1): 170 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T R L Griffiths and J K Mellon Evolving immunotherapeutic strategies in bladder and renal cancer Postgrad. Med. J., June 1, 2004; 80(944): 320 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. I. Rini, S. Halabi, J. Taylor, E. J. Small, and R. L. Schilsky Cancer and Leukemia Group B 90206: A Randomized Phase III Trial of Interferon-{alpha} or Interferon-{alpha} Plus Anti-Vascular Endothelial Growth Factor Antibody (Bevacizumab) in Metastatic Renal Cell Carcinoma Clin. Cancer Res., April 15, 2004; 10(8): 2584 - 2586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Negrier Better Survival With Interleukin-2-Based Regimens? Possibly Only in Highly Selected Patients J. Clin. Oncol., April 1, 2004; 22(7): 1174 - 1176. [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Li, A. Carr, F. Ito, S. Teitz-Tennenbaum, and A. E. Chang Polarization Effects of 4-1BB during CD28 Costimulation in Generating Tumor-reactive T Cells for Cancer Immunotherapy Cancer Res., May 15, 2003; 63(10): 2546 - 2552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Motzer Renal Cell Carcinoma: A Priority Malignancy for Development and Study of Novel Therapies J. Clin. Oncol., April 1, 2003; 21(7): 1193 - 1194. [Full Text] [PDF]
|
|
|
|
|
|
C. Uherek, T. Tonn, B. Uherek, S. Becker, B. Schnierle, H.-G. Klingemann, and W. Wels Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction Blood, July 30, 2002; 100(4): 1265 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kono, A. Takahashi, F. Ichihara, H. Amemiya, H. Iizuka, H. Fujii, T. Sekikawa, and Y. Matsumoto Prognostic Significance of Adoptive Immunotherapy with Tumor-associated Lymphocytes in Patients with Advanced Gastric Cancer: A Randomized Trial Clin. Cancer Res., June 1, 2002; 8(6): 1767 - 1771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Motzer, J. Bacik, T. Mariani, P. Russo, M. Mazumdar, and V. Reuter Treatment Outcome and Survival Associated With Metastatic Renal Cell Carcinoma of Non-Clear-Cell Histology J. Clin. Oncol., May 1, 2002; 20(9): 2376 - 2381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Mitchell, D. Darrah, D. Yeung, S. Halpern, A. Wallace, J. Voland, V. Jones, and J. Kan-Mitchell Phase I Trial of Adoptive Immunotherapy With Cytolytic T Lymphocytes Immunized Against a Tyrosinase Epitope J. Clin. Oncol., February 15, 2002; 20(4): 1075 - 1086. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Falk, E. Noessner, E. H. Weiss, and D. J. Schendel Retaliation against Tumor Cells Showing Aberrant HLA Expression Using Lymphokine Activated Killer-derived T Cells Cancer Res., January 1, 2002; 62(2): 480 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Q. Phan, P. Attia, S. M. Steinberg, D. E. White, and S. A. Rosenberg Factors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic Melanoma J. Clin. Oncol., August 1, 2001; 19(15): 3477 - 3482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Hillman, R. L. Maughan, D. J. Grignon, M. Yudelev, J. Rubio, S. Tekyi-Mensah, A. Layer, M. Che, and J. D. Forman Neutron or Photon Irradiation for Prostate Tumors: Enhancement of Cytokine Therapy in a Metastatic Tumor Model Clin. Cancer Res., January 1, 2001; 7(1): 136 - 144. [Abstract] [Full Text]
|
|
|
|
|
|
X. Xu, P. Clarke, G. Szalai, J. E. Shively, L. E. Williams, Y. Shyr, E. Shi, and F. J. Primus Targeting and Therapy of Carcinoembryonic Antigen-expressing Tumors in Transgenic Mice with an Antibody-Interleukin 2 Fusion Protein Cancer Res., August 1, 2000; 60(16): 4475 - 4484. [Abstract] [Full Text]
|
|
|
|
|
|
P. B. Chapman, L. H. Einhorn, M. L. Meyers, S. Saxman, A. N. Destro, K. S. Panageas, C. B. Begg, S. S. Agarwala, L. M. Schuchter, M. S. Ernstoff, et al. Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma J. Clin. Oncol., September 1, 1999; 17(9): 2745 - 2745. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Shaw, A. A. Maung, R. J. Steptoe, A. W. Thomson, and N. L. Vujanovic3 Expansion of Functional NK Cells in Multiple Tissue Compartments of Mice Treated with Flt3-Ligand: Implications for Anti-Cancer and Anti-Viral Therapy J. Immunol., September 15, 1998; 161(6): 2817 - 2824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Porgador, O. Mandelboim, N. P. Restifo, and J. L. Strominger Natural killer cell lines kill autologous beta 2-microglobulin-deficient melanoma cells: Implications for cancer immunotherapy PNAS, November 25, 1997; 94(24): 13140 - 13145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. M. N. QUEZADO, W. KARZAI, R. L. DANNER, B. D. FREEMAN, L. YAN, P. Q. EICHACKER, S. M. BANKS, J. PERREN COBB, R. E. CUNNION, M. J. N. QUEZADO, et al. Effects of L-NMMA and Fluid Loading on TNF-induced Cardiovascular Dysfunction in Dogs Am. J. Respir. Crit. Care Med., May 1, 1997; 157(5): 1397 - 1405. [Abstract] [Full Text]
|
|